Lakefront Biotherapeutics NV (ENXTAM: LKFT)
Health Care · Biotechnology · BE
€25.44
+2.75% today · -7.0% 1Y
Lakefront Biotherapeutics NV (ENXTAM: LKFT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.93B and employs 452 people.
Over the last twelve months the share price has lost 7.0%, trading between 22.32 and 32.74.
Tweenvest scores Lakefront Biotherapeutics NV across four factors: quality 54/100, value 60/100, growth 79/100. Its strongest factor is growth.
LKFT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.93B
- Revenue (TTM)
- $1.13B
- P/E
- 2.82
- EPS
- 9.05
- Dividend yield
- —
- Beta (5Y)
- 0.11
- 52-week high
- €32.74
- 52-week low
- €22.32
- Avg volume (3M)
- —
- Shares outstanding
- 64.98M
- Employees
- 452
- Next earnings
- —
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
- ISIN
- BE0003818359
- Founded
- 1999
- Listed since
- May 6, 2005
- Exchange
- Euronext Amsterdam
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.09 | -0.46% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.